The content on this site is intended for healthcare professionals only
Dr Shaji Kumar presents results at the 2019 European Hematology Association (EHA) Annual Meeting from a study looking at the addition of venetoclax to bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
The trial randomised patients between venetoclax or placebo with bortezomib and dexamethasone and although patients receiving venetoclax saw an improved response and progression-free survival, there was an increase in treatment-emergent deaths.
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
ASCO 2024: Lung cancer highlights
More effective treatment options required for patients with MM post lenalidomide exposure
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma
ADCLEC.syn1 and CD33-CARS in humanised acute myeloid leukaemia models shows promising efficacy
Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens
